Biotechnology company Inovio Pharmaceuticals Inc (NASDAQ:INO) stated on Tuesday its net loss of USD97.0m (USD1.05 per basic and diluted share) for the year ended 31 December 2018.
This marks a decline in earnings when compared with a lower net loss of USD88.2m (USD1.08 per basic and USD1.09 per diluted share) in 2017.
Total revenue of USD30.5m was generated for the year ended 31 December 2018, down over total revenue of USD42.2m in 2017.
The company said the year over year decrease in comparable revenue and grant agreement recognition was primarily due to lower revenues recognised under its collaborative research and development agreement with AstraZeneca, a decrease in grant funding recognised from its DARPA Ebola grant as well as no revenue recognised in 2018 from Roche due to the termination of the agreement in 2017.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy